Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide thumbnail

Our Mission

HealthTell’s mission is to provide the most accurate and affordable diagnostic for early disease detection—all from a simple drop of blood.

Technology

The HealthTell Immunosignature technology measures a person’s real-time response to disease. We analyze the binding patterns of an individual’s antibodies to our proprietary peptide arrays. These binding patterns provide highly accurate insight into the presence and nature of specific diseases.

Slide thumbnail

The Power of Peptide Arrays

HealthTell’s proprietary arrays contain high-density peptides synthesized on silicon wafers. These peptides are designed to be as diverse as possible. Thousands of antibodies are captured on a single array. The presence or absence of specific antibody binding patterns can then be correlated back to specific disease states.

Slide thumbnail

A New Disease Monitoring Platform

Immunosignatures provide real-time monitoring of an individual’s immune system. This new approach often yields more accurate and sensitive measurements than traditional biomarker or imaging approaches.

Our Mission

HealthTell’s mission is to provide the most accurate and affordable diagnostic for early disease detection—all from a simple drop of blood.

Technology Core

The HealthTell Immunosignature technology measures a person’s real-time response to disease. We analyze the binding patterns of an individual’s antibodies to our proprietary peptide arrays. These binding patterns provide highly accurate insight into absence or presence of disease.

The Power of Peptide Arrays

HealthTell’s proprietary arrays contain over 300,000 peptide chains synthesized on silicon chips. These peptides bind with specific disease antibodies and are illuminated during the analysis phase and classified based on a precise disease algorithm.

A New Disease Monitoring Platform

The Process

Collect

 The test is simple. The physician administered kit includes a small lancet which is used to prick the finger. A single drop of blood will then be placed on a sample collection card and mailed to HealthTell’s laboratory in a self-addressed stamped envelope.

Measure

The measurement is accurate. Each blood drop will be analyzed for specific binding patterns on our proprietary peptide arrays. The patterns indicate, based on a trained algorithm, specific disease states.

Results

The results are actionable. Clinicians will use the results to help determine the next steps in the diagnostic and therapeutic continuum. Results will be provided within days from the initial sample collection to the physician.

Changing the Face of Diagnostics. One Publication at a Time.

publications-b-01

“Application of immunosignatures to the assessment of Alzheimer’s disease”

– Annals of Neurology, 2011
Authors: Restrepo L, Stafford P, Magee DM, Johnston SA.

Accurate assessment of Alzheimer’s disease (AD), both pre-symptomatically and at different disease stages, will become increasingly important with the expanding elderly population. There are a number of indications that the immune system is engaged in AD…
View Publication

publications-b-01

“Scalable High-Density Peptide Arrays for Comprehensive Health Monitoring”

– Nature Communications, 2014
Authors: Legutki JB, Zhao ZG, Greving M, Woodbury N, Johnston SA, Stafford P.

There is an increasing awareness that health care must move from post-symptomatic treatment to presymptomatic intervention. An ideal system would allow regular inexpensive monitoring of health status using circulating antibodies to report on health fluctuations. Recently, we demonstrated that peptide microarrays can do this through antibody signatures (immunosignatures)…
View Publication

publications-b-01

“Application of immunosignatures to the assessment of Alzheimer’s disease”

– Annals of Neurology, 2011
Authors: Restrepo L, Stafford P, Magee DM, Johnston SA.

Accurate assessment of Alzheimer’s disease (AD), both pre-symptomatically and at different disease stages, will become increasingly important with the expanding elderly population. There are a number of indications that the immune system is engaged in AD…
View Publication

publications-b-01

“Evaluation of Biological Sample Preparation for Immunosignature-Based Diagnostics”

– Clinical and Vaccine Immunology, 2012
Authors: Chase BA, Johnston SA and Legutki JB.

Immunosignatures derived from dried blood were capable of distinguishing naïve mice from those infected with influenza virus. Saliva was applied to the arrays, and the IgA immunosignature correlated strongly with that from dried blood…
View Publication

publications-b-01

“Feasibility of an early Alzheimer’s disease immunosignature diagnostic test”

– Journal of Neuroimmunology, 2012
Authors: Restrepo L, Stafford P, Johnston SA.

A practical diagnostic test is needed for early Alzheimer’s disease (AD) detection. Immunosignaturing, a technology that employs antibody binding to a random-sequence peptide microarray, generates profiles that distinguish transgenic mice engineered with familial AD mutations (APPswe/PSEN1-dE9)…
View Publication

publications-b-01

“Immunosignaturing: a critical review”

– Cell Press, 2012
Authors: Sykes K., Legutki JB, Stratford P.

Health is a complex interaction between metabolism, physiology, and immunity. Although it is difficult to define quantitatively, the activity of the humoral immune system provides a reasonable proxy for changes in health. Immunosignaturing is a microarray-based technology that quantitates the dynamics of circulating antibodies. Recent advancements in the field warrant a review of the technology…
View Publication

publications-b-01

“Immunosignatures can predict vaccine efficacy”

– PNAS, 2013
Authors: Legutki JB, Johnston SA.

Vaccines have been the most important medical intervention developed, yet vaccines for many diseases are still needed. Despite its success, the process to develop a vaccine remains empirical, resting on measuring the number of vaccinees that incur or do not incur an infection. Here we test in the mouse flu model whether the “immunosignature” diagnostic technology could be applied to predict vaccine efficacy…
View Publication

publications-b-01

“Application of Immunosignatures to Diagnosis of Valley Fever”

– Clinical and Vaccine Immunology, 2014
Authors: Navalkar KA, Johnston SA, Woodbury N, Galgiani J, Magee DM, Chicacz Z, Stafford P.

Valley fever (VF) is difficult to diagnose, partly because the symptoms of VF are confounded with those of other community-acquired pneumonias. Confirmatory diagnostics detect IgM and IgG antibodies against coccidioidal antigens via immunodiffusion (ID)…
View Publication

publications-b-01

“Diagnosis and Early Detection of CNS-SLE in MRL/lpr Mice Using Peptide Microarrays”

– BMC Immunology, 2014
Authors: Williams S, Stafford P, Hoffman SA.

These results indicate that immunosignaturing could predict and diagnose lupus and its CNS manifestations. It can also be used to characterize pathogenic autoantibodies, which may help to better understand the underlying mechanisms of CNS-Lupus. (PDF)
View Publication

publications-b-01

“Immunosignature System for Diagnosis of Cancer”

– PNAS, 2014
Authors: Stafford P, Cichacz Z, Woodbury N, Johnston SA.

Over much of the world, healthcare systems are facing an unprecedented challenge to meet the medical needs of an aging population while controlling costs. The early detection and treatment of diseases that are prevalent in older people is likely to be a key aspect of economically efficient, high-quality healthcare. In the case of cancer, the resection of a stage I or stage II tumor is often effectively a cure…
View Publication

For a Full List of Publications:
Click Here

World-class Professionals with a Common Goal: Better Health Diagnostics.

“HealthTell will revolutionize disease diagnostics.”

Bill Colston, PhD
CEO, HealthTell

Our leadership team is inspired to change the diagnostic industry forever. From early detection to better health economics, HealthTell is built on the foundation that improving the technology and experience available to patients today, will help them live better, healthier tomorrow.

About Our Leadership Team

“A technology capable of detecting the presence of disease, with a simple drop of blood, would revolutionize cancer diagnosis.”

Paul A. Bunn, Jr., MD
Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research

HealthTell continues to partner with world renown leaders in the healthcare industry who are motivated to improve outcomes and decrease expenditures by leveraging the power of ImmunoSignatures.
Learn more about Our Clinical Advisors

“Investment in a company is more than just the financial returns, it is also about the societal impact the company hopes to make with their technology. HealthTell will disrupt disease diagnostics providing a needed improvement in medicine.”

Paul Conley, PhD
Managing Director, Paladin Capital Group

About Our Board of Directors

HealthTell Investors Include:

 

About Our Investors

HealthTell is collaborating with world renown universities, hospitals, and clinical researchers. Our technology has endless possible applications to impact clinical utility, drug development, and biotechnology.

About Our Partnerships

Our Vision

“HealthTell will revolutionize disease diagnostics.”

– Bill Colston, PhD
CEO, HealthTell

Our leadership team is inspired to change the diagnostic industry forever. From early detection to better health economics, HealthTell is built on the foundation that improving the technology and experience available to patients today, will help them live better, healthier tomorrow.

About Our Leadership Team

Clinical Advisors

“A technology capable of detecting the presence of disease, with a simple drop of blood, would revolutionize cancer diagnosis.”

– Paul A. Bunn, Jr., MD
Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research

HealthTell continues to partner with world renown leaders in the healthcare industry who are motivated to improve outcomes nad decrease expenditures by leveraging the power of ImmunoSignatures.

Learn more about Our Clinical Advisors

Board of Directors

“Investment in a company is more than just the financial returns, it is also about the societal impact the company hopes to make with their technology. HealthTell will disrupt disease diagnostics providing a needed improvement in medicine.”

– Paul Conley, PhD
Managing Director, Paladin Capital Group

About Our Board of Directors

Investors

HealthTell Investors Include:

About Our Investors

Collaborators

HealthTell is collaborating with world renown universities, hospitals, and clinical researchers. Our technology has endless possible applications to impact clinical utility, drug development, and biotechnology.

About Our Partnerships

Featured Jobs:

  • (No Available Positions)

Join our Team

HealthTell is a company filled with passionate, data driven, and collaborative professionals, considered world class in their area of expertise. We are hiring people with entrepreneurial spirits to help develop new applications for our platform that positively impact people’s health.

HealthTell has two regional sites in San Ramon, California and Chandler, Arizona. These locations are strategically designed to provide access to key industry talent in business, technical, and manufacturing disciplines.

Want to be an integral part of the diagnostic revolution? Please explore our open career opportunities or feel free to contact us for further information.





 General/Product Clinician Investors Press/News Information Scientific/Collaborators Other